Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva announced new clinical data from multiple studies demonstrating that AUSTEDO and AUSTEDO XR (deutetrabenazine) reduce symptoms in tardive dyskinesia patients across severity levels. The IMPACT-TD Registry showed improvements in abnormal involuntary movements and daily living activities in mild TD cases, while the RIM-TD study found over 50% of patients achieved clinically meaningful response by week 15, with additional improvements continuing with sustained treatment. A caregiver education initiative also improved TD diagnosis rates.